‘Boosting the immune therapy efficacy with proteasome inhibitors in Mantle Cell Lymphoma’
Boosting the immune therapy efficacy with proteasome inhibitors in Mantle Cell Lymphoma
An SWG Grant-supported project initiated by the SWG on Immune Therapies for Hematologic Disorders
Full project title
Project lead
Dr Adrian Bogdan Țigu
Scientific Researcher at ICB-MEDFUTURE – Department of Personalized Medicine and Rare Diseases, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
Project background and aims
The project aims to use proteasome inhibitors to block ROR1 degradation in Mantle Cell Lymphoma cells and to enhance the CAR-T cells and mAbs efficacy against the target.
Proteasome inhibitors can enhance the efficacy of targeted therapies in Mantle Cell Lymphoma by disrupting the protein homeostasis, inhibiting NF-kB signaling and by inducing cell death. The combination of Proteasome inhibitors with anti ROR1 targeted therapies can results in an enhanced apoptosis and inhibition of key survival pathways.
Testing the combination of Proteasome inhibitors with targeted therapies using preclinical models will provide valuable insights into the molecular mechanisms that can be modulated to improve clinical outcomes for relapse/refractory Mantle Cell Lymphoma patients.